ValiRx plc ( (GB:VAL) ) has issued an update.
ValiRx PLC has issued a director disclosure update concerning its Chairman, Martin Gouldstone, who is also a director at Oncimmune Holdings PLC. Oncimmune Holdings has announced its intention to appoint administrators. This update highlights potential implications for ValiRx’s governance and stakeholder interests, although no further disclosures are required under AIM Rules.
More about ValiRx plc
ValiRx PLC is a life sciences company focused on early-stage cancer therapeutics and women’s health. The company accelerates the translation of innovative science into impactful medicines to improve patient lives. ValiRx provides a framework for the rapid translation of novel drug candidates into clinical development, working closely with collaborators to streamline the drug development process. The company is listed on the AIM Market of the London Stock Exchange under the ticker symbol VAL.
YTD Price Performance: -23.08%
Average Trading Volume: 10,207,666
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.25M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com